Phentolamine Mesylate/Papaverine Hydrochloride(Phentolamine Mesylate/Papaverine Hydrochloride) - 药物靶点：PDE10A x adrenergic receptor_在研适应症：勃起功能障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Androskat

靶点

PDE10A x adrenergic receptor

作用方式

抑制剂、拮抗剂

作用机制

PDE10A抑制剂(磷酸二酯酶10A抑制剂)、adrenergic receptor拮抗剂(肾上腺素能受体家族拮抗剂)

治疗领域

泌尿生殖系统疾病

在研适应症

勃起功能障碍

非在研适应症-

原研机构

zr pharma& GmbH

在研机构

zr pharma& GmbH

非在研机构-

最高研发阶段批准上市

首次获批日期

荷兰 (1996-12-04),

勃起功能障碍

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 Phentolamine Mesylate/Papaverine Hydrochloride 相关的临床结果

登录后查看更多信息

100 项与 Phentolamine Mesylate/Papaverine Hydrochloride 相关的转化医学

登录后查看更多信息

100 项与 Phentolamine Mesylate/Papaverine Hydrochloride 相关的专利（医药）

登录后查看更多信息

1

项与 Phentolamine Mesylate/Papaverine Hydrochloride 相关的文献（医药）

1993-11-01·Der Urologe. Ausg. A4区 · 医学

Effektivität und Sicherheit der Schwellkörper-Autoinjektionstherapie mit Papaverin/Phentolamin. Studiengruppe.

4区 · 医学

Article

作者: Hartmann, U ; Thon, W F

A multicenter long-term study at 13 urologic clinics in Germany and Austria tested the efficacy and safety of a papaverine (15 mg/ml) and phentolamine (0.5 mg/ml) mixture (ANDROSKAT) in achievement of pharmacologically aided erection. The study population of 157 men with chronic erectile dysfunction received a total of 559 injections administered by physicians, to establish the individual minimal dose of the mixture needed by each patient for a rigid erection. Rigidity sufficient for intercourse was achieved by 94% of these men. In the second phase of the study, 92 men administered a total of 4717 self-injections (mean 51.2, SD 7.7), with an average follow-up of 14 months. The mean therapeutic dose was 1.02 ml (SD 0.72). The latency time to full erection averaged 10.3 min (SD 5.5). The average duration of the erection induced was 67.1 min (SD 40.8, min. 11.2, max. 236). Sexual intercourse, orgasm and ejaculation were reported following 90%, 88% and 86%, respectively, of all injections. In the initial diagnostic phase, prolonged erections were seen in 13 patients (3%) and minor bruises at the injection site in 12 men. Side effects of self-injection during home therapy were pain (1.2%), haematoma (2.6%) and prolonged erection (0.9%). We conclude that self-injection with a combination of papaverine and phentolamine is an efficient and safe long-term treatment for erectile dysfunction.

100 项与 Phentolamine Mesylate/Papaverine Hydrochloride 相关的药物交易

登录后查看更多信息